PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer chemotherapy and pharmacology, 2013 - Springer
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …
被引用次数：261 相关文章

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer chemotherapy and pharmacology, 2013 - pubmed.ncbi.nlm.nih.gov
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently
dysregulated kinase cascades in human cancer. Molecular alterations in these pathways …

[引用][C] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer Chemotherapy and Pharmacology, 2013 - cir.nii.ac.jp
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.

CD Britten - Cancer Chemotherapy and Pharmacology, 2013 - europepmc.org
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently
dysregulated kinase cascades in human cancer. Molecular alterations in these pathways …

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer Chemotherapy and Pharmacology, 2013 - infona.pl
The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently
dysregulated kinase cascades in human cancer. Molecular alterations in these pathways …

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.

C Britten - Cancer Chemotherapy & Pharmacology, 2013 - search.ebscohost.com
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …

[引用][C] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD BRITTEN - Cancer chemotherapy and pharmacology, 2013 - pascal-francis.inist.fr
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD Britten - Cancer Chemotherapy and Pharmacology, 2013 - search.proquest.com
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …

PI3K and MEK inhibitor combinations: Examining the evidence in selected tumor types

CD Britten - Cancer Chemotherapy and Pharmacology, 2013 - hero.epa.gov
Abstract The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most
frequently dysregulated kinase cascades in human cancer. Molecular alterations in these …

[引用][C] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

CD BRITTEN - Cancer chemotherapy and pharmacology, 2013 - Springer